Shopping Cart
- Remove All
Your shopping cart is currently empty
CCG258208
😃Good
Catalog No. T13714Cas No. 2055990-90-2
Alias GRK2-IN-1
GRKs-IN-1 has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM).
CCG258208
😃Good
Catalog No. T13714Alias GRK2-IN-1Cas No. 2055990-90-2
GRKs-IN-1 has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,570 | 3-6 months | |
| 50 mg | $3,380 | 3-6 months | |
| 100 mg | $4,600 | 3-6 months |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CCG258208"
Takeda103A
Takeda-103-A, Takeda-103A, Takeda 103 A, CMPD-103A, CMPD103A
T24850865609-72-9
Takeda103A (CMPD103A) is the GRK2-dependent bovine tubulin oxidation effective inhibitor.
- $77
Size
QTY
CMPD101
T14989865608-11-3
CMPD101 is a membrane-permeable small-molecule inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM). Which can be used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively.
- $60
Size
QTY
CCG215022
T34981813527-81-9
CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM for GRK2, 0.38±0.06 μM for GRK5, and 3.9±1 μM for GRK1.
- $97
Size
QTY
GSK180736A
GSK180736
T3513817194-38-0
GSK180736A is an effective and selective GRK2 inhibitor (IC50: 0.77 μM) and >100-fold selectivity over other GRKs. It is a weak inhibitor of PKA (IC50: 30 μM), but highly effective against ROCK1 (IC50: 100 nM).
- $35
Size
QTY
GSK270822A
GSK-270822A, GSK 270822A
T27467864082-23-5In house
GSK270822A is a selective ROCK1 inhibitor. GSK270822A exhibits IC50 of 9nM, 1100nM, 1550nM for ROCK1, RSK1, p70S6K, respectively.
- $143
Size
QTY
GRK5-IN-2
T96091642839-27-7
GRK5-IN-2, a pyridine-based bicyclic compound, is a potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor. It regulates the expression and/or release of insulin and is useful for the metabolic disease research.
- $30
Size
QTY
Paroxetine hydrochloride
Cited
Paroxetine HCl, FG-7051, BRL29060A, BRL29060 hydrochloride
T163678246-49-8
Paroxetine hydrochloride (Paroxetine HCl) is a serotonin uptake inhibitor that is effective in the treatment of depression.
- $45
Size
QTY
CitedGRK2-IN-1 hydrochloride (2055990-90-2 free base)
GRK2-IN-1 hydrochloride
T13714L
GRKs-IN-1 hydrochloride has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM).
- $2,420
Size
QTY
GRK6-IN-2
T615562677786-27-3
GRK6-IN-2 is a potent G protein-coupled receptor kinase 6 (GRK6) inhibitor with potential antitumor activity.GRK6-IN-2 has been studied in multiple myeloma.
- $56
Size
QTY
GSK299115A
GSK-299115A, GSK 299115A
T27471864082-35-9In house
GSK299115A (GSK-299115A) is a selective ROCK1 Inhibitor. GSK299115A exhibits IC50 of 8nM, 620nM, 560nM for ROCK1, RSK1, p70S6K, respectively.
- $336
Size
QTY
1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID
T8913260555-42-8
1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID targets GRK2.
- $30
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | GRKs-IN-1 has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM). |
| Targets&IC50 | GRK5:7.1 μM, GRK2:30 nM |
| In vitro | GRKs-IN-1 (Compound 14as) is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine. |
| Alias | GRK2-IN-1 |
| Molecular Weight | 452.48 |
| Formula | C24H25FN4O4 |
| Cas No. | 2055990-90-2 |
| Relative Density. | 1.314 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CCG258208 | purchase CCG258208 | CCG258208 cost | order CCG258208 | CCG258208 chemical structure | CCG258208 in vitro | CCG258208 formula | CCG258208 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.